Repurposing FDA-approved drugs against multiple proteins of SARS-CoV-2: An in silico study

The current crisis of the COVID-19 pandemic around the world has been devastating as many lives have been lost to the novel SARS CoV-2 virus. Thus, there is an urgent need for the right therapeutic drug to curb the disease. However, there is time constraint in drug development, hence the need for dr...

Descripción completa

Detalles Bibliográficos
Autores principales: Akinlalu, Alfred Olaoluwa, Chamundi, Annapoorna, Yakumbur, Donald Terseer, Afolayan, Funmilayo I. Deborah, Duru, Ijeoma Akunna, Arowosegbe, Michael Aderibigbe, Enejoh, Ojochenemi Aladi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Authors. Published by Elsevier B.V. on behalf of African Institute of Mathematical Sciences / Next Einstein Initiative. 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8272888/
https://www.ncbi.nlm.nih.gov/pubmed/34308004
http://dx.doi.org/10.1016/j.sciaf.2021.e00845

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8272888/
https://www.ncbi.nlm.nih.gov/pubmed/34308004
http://dx.doi.org/10.1016/j.sciaf.2021.e00845

Ejemplares similares